Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AACR, adequacy, AdV, allocytotoxicity, alpha, AMT, anesthesiologist, articulating, autoleucel, bargaining, beneficiary, beta, Biden, biology, biometric, Brazil, breakdown, Brexit, brexucabtagene, Breyanzi, Britain, Bruton, CCPA, cessation, Charcot, client, climate, closure, CMC, Commissioner, consecutive, constituted, constitutionality, constraint, Cooperation, CPRA, crime, cyber, cybersecurity, de, deal, delete, deployment, depressed, depth, dissemination, distancing, diverge, double, downtime, duty, economy, editing, EEA, EEO, England, enrichment, entertainment, episodic, ESMO, exfiltration, Exposition, fear, featured, fenebrutinib, formal, forum, foundation, GDPR, gene, Geral, Great, guide, hand, honoring, hostile, HSCT, idecabtagene, immunodeficiency, injured, innate, intangible, intensify, interdependent, interplay, interrelated, IORA, IRC, Johnson, JSC, Kesimpta, killing, leakage, Lei, LGPD, licensee, light, living, MAA, magnitude, malfeasance, malfunction, malware, mark, mathematical, max, mechanism, mentioned, MHRA, min, misused, movement, nationwide, nonrefundable, Northern, nose, notification, nurse, OLE, onsite, ordinary, OS, outset, ovarian, pandemic, pathology, pattern, pause, paused, PDCO, perfusion, permanently, phenotype, pioneer, polyfunctional, pose, poster, predominant, principle, proportion, pseudonymized, quantification, quarantine, radiographic, ransomware, ratified, RCT, reallocation, recession, reconsider, recourse, reevaluate, referendum, regime, reinstated, reinvested, reject, rejection, reliant, remote, remotely, representation, residence, residency, resume, retention, Rhinorrhea, run, runny, Sanofi, satisfaction, Scotland, SDI, Secretary, sequester, serial, shelter, Shield, simultaneously, SITC, slight, slowly, sophistication, Southern, SSP, standalone, steering, stolen, streamline, stricter, stringent, sue, tariff, TecartusTM, temporarily, terrorist, theft, tie, timepoint, transcriptional, transient, transportation, trusted, turnover, uncollectible, unconditional, unnecessary, unusual, usability, vacancy, vicleucel, Virtual, vivo, workforce, wrongful
Removed:
agonist, algorithm, biotin, capitalization, Celgene, children, compassionate, comprise, concentrated, copy, deregulation, easier, elimination, entry, escalating, Extavia, fire, flat, fumarate, hiring, indefinite, insolvency, irrevocable, judged, manmade, marginal, MatchMe, MedDay, mitoxantrone, modifying, ofatumumab, offshore, perpetual, plc, purpose, repatriated, repealing, siponimod, transformed, vulnerability
Filing tables
Filing exhibits
Associated ATRA transcripts
ATRA similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in registration statements No. 333-199508, No. 333-204076, No. 333-209961, No. 333-214431, No. 333-219763, No. 333-223254, No. 333-229861, No. 333-236704, and No. 333-249976 on Form S-8 of our reports dated March 1, 2021, relating to the consolidated financial statements of Atara Biotherapeutics, Inc. and subsidiaries (the “Company”) and the effectiveness of the Company’s internal control over financial reporting, appearing in this Annual Report on Form 10-K of Atara Biotherapeutics, Inc. for the year ended December 31, 2020.
/s/ DELOITTE & TOUCHE LLP
San Jose, California
March 1, 2021